ASH: An­oth­er 'off-the-shelf' cell ther­a­py leader shows dura­bil­i­ty is­sues, rais­ing re­newed con­cerns about emerg­ing field

The next gen­er­a­tion of cell ther­a­pies have fo­cused in large part on the de­vel­op­ment of al­lo­gene­ic — bet­ter known as “off-the-shelf — drugs that can cut man­u­fac­tur­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER